{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T16:56:49Z","timestamp":1794589009900,"version":"4.9.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.msard.2024.105868","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T17:25:51Z","timestamp":1725470751000},"page":"105868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Heterogenous relapse and efficacy endpoint definitions for neuromyelitis optica spectrum disorder studies: A systematic review"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8689-5148","authenticated-orcid":false,"given":"Rebeka Bustamante","family":"Rocha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Ferreira","family":"Bomtempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Claudia Benevides","family":"Tadinac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Abrahao","family":"Allioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Diogo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo Mota","family":"Telles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.msard.2024.105868_bib0001","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1001\/archneurol.2012.545","article-title":"Lack of response to pulse cyclophosphamide in neuromyelitis optica: evaluation of 7 patients","volume":"69","author":"Bichuetti","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2024.105868_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102475","article-title":"Brain MRI characteristics in neuromyelitis optica spectrum disorders: a large multi-center retrospective study in China","volume":"46","author":"Cao","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2024.105868_bib0003","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12014-024-09466-9","article-title":"The relationship between serum astroglial and neuronal markers and AQP4 and MOG autoantibodies","volume":"21","author":"Chatanaka","year":"2024","journal-title":"Clin. Proteomics"},{"issue":"3","key":"10.1016\/j.msard.2024.105868_bib0004","first-page":"2","article-title":"Neuromyelitis optica spectrum disorder: a rare cause of spinal cord and optic nerve involvement","volume":"14","author":"Douedi","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.msard.2024.105868_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/174720","article-title":"Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis","volume":"2015","author":"Etemadifar","year":"2015","journal-title":"Mult. Scler. Int."},{"issue":"2","key":"10.1016\/j.msard.2024.105868_bib0006","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin. Med."},{"issue":"1","key":"10.1016\/j.msard.2024.105868_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.105868_bib0008","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.msard.2024.105868_bib0009","first-page":"1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.msard.2024.105868_bib0010","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2024.105868_bib0011","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/cns.13836","article-title":"Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): novel insights into therapeutic possibilities in NMOSD","volume":"28","author":"Shi","year":"2022","journal-title":"CNS Neurosci. Ther."},{"issue":"7","key":"10.1016\/j.msard.2024.105868_bib0012","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/cns.13836","article-title":"Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): novel insights into therapeutic possibilities in NMOSD","volume":"28","author":"Shi","year":"2022","journal-title":"CNS Neurosci. Ther."},{"issue":"4","key":"10.1016\/j.msard.2024.105868_bib0013","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00415-019-09649-7","article-title":"Effects of immunotherapies and prognostic predictors in neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"267","author":"Shi","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105868_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101506","article-title":"A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX","volume":"38","author":"Songthammawat","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105868_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2023.1130971","article-title":"New advancements in the management of Neuromyelitis Optica spectrum disease: literature review","volume":"3","author":"Sudhakar","year":"2023","journal-title":"Front. Ophthalmol."},{"issue":"4","key":"10.1016\/j.msard.2024.105868_bib0016","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/1744-9987.13456","article-title":"Retrospective study of the adverse events of the treatment for an acute attack of neuromyelitis optica spectrum disorder","volume":"24","author":"Veerachit-O-larn","year":"2020","journal-title":"Ther. Apher. Dial"},{"issue":"17","key":"10.1016\/j.msard.2024.105868_bib0017","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1212\/WNL.0000000000001520","article-title":"Challenges and opportunities in designing clinical trials for neuromyelitis optica","volume":"84","author":"Weinshenker","year":"2015","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2024.105868_bib0019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2024.105868_bib0020","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"4","key":"10.1016\/j.msard.2024.105868_bib0021","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s10072-021-05609-0","article-title":"Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors","volume":"43","author":"Zhang","year":"2022","journal-title":"Neurol. Sci."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T04:30:14Z","timestamp":1732336214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824004449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":20,"alternative-id":["S2211034824004449"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105868","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogenous relapse and efficacy endpoint definitions for neuromyelitis optica spectrum disorder studies: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105868"}}